Curated Information
Javascript is not enabled on this browser. This site will not work properly without Javascript.
PhosphoSitePlus Homepage PhosphoSitePlus® v6.5.9.2
Powered by Cell Signaling Technology
Home > Curated Information Page > PubMed Id: 17334399
Kehn K, et al. (2007) Functional consequences of cyclin D1/BRCA1 interaction in breast cancer cells. Oncogene 26, 5060-9 17334399
This page summarizes selected information from the record referenced above and curated into PhosphoSitePlus®, a comprehensive online resource for the study of protein post-translational modifications (NAR, 2015, 43:D512-20). To learn more about the scope of PhosphoSitePlus®, click here.
Click on the protein name to open the protein page, and on the RSD number to open the site page.

S632-p - BRCA1 (human)
Modsite: LVVSRNLsPPNCTEL SwissProt Entrez-Gene
Orthologous residues
BRCA1 (human): S632‑p, BRCA1 iso6 (human): , BRCA1 iso7 (human): S632‑p, BRCA1 (mouse): S625‑p, BRCA1 (rat): S625‑p
Methods used to characterize site in vivo mutation of modification site
Relevant cell lines - cell types - tissues:  MCF-7 (breast cell)
Cellular systems studied:  cell lines
Species studied:  human
Enzymes shown to modify site in vitro
Type Enzyme
KINASE CDK4 (human)
Comments:  Cdk4 in complex with cyclin D1
Upstream Regulation
Potential in vivo enzymes for site: 
Type Enzyme Evidence Notes
KINASE CDK4 (human) pharmacological inhibitor of upstream enzyme, antisense inhibition of upstream enzyme
Treatments, proteins and their effect on site modification: 
Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes
fascaplysin decrease
siRNA decrease siRNA against Cdk4